We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protofibrils May Be Culprits in Type II Diabetes

By Biotechdaily staff writers
Posted on 05 Nov 2003
Researchers have found that protofibrils, precursor molecules for the amyloid fibrils that are characteristic of type II diabetes, are better able to penetrate cell membranes and have greater potential to cause damage than do the mature fibrils.

Investigators at Tel Aviv University (Israel; www.tau.ac.il) used colorimetric and fluorescent assays as well as electron microscopy to study the membrane interaction activity of soluble and insoluble islet amyloid polypeptide assemblies at high temporal resolution. More...
They reported in the September 23, 2003, issue of Biochemistry that their results provided experimental evidence for the formation of transient soluble prefibrillar assemblies, which were highly membrane-active.

"Type II diabetes is one of the most common amyloid-related diseases,” explained senior author Dr. Ehud Gazit, lecturer in the department of molecular microbiology and biotechnology at Tel Aviv University. "A very interesting point is the striking similarity between these assemblies and the structures observed in the cases of Alzheimer's disease and Parkinson's disease,” said Dr. Gazit.



Related Links:
Tel Aviv University

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Hematology Consumables
Bioblood Devices
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Photo courtesy of Adobe Stock

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.